Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and outstanding securities.

The deal has already been unanimously approved by both companies’ board of directors and will next face Cybin’s shareholders meeting on or about October 12.

Small Pharma shareholders would receive 0.2409 Cybin common shares per each common share held, taking $0.10 as the exchange ratio based on Cybin shares’ closing price on Cboe Canada (ex NEO) on Aug. 25, plus Small Pharma’s trading price on the TSX Venture Exchange for the period ended Aug. 25. 

As of Monday, August 28, existing Cybin shareholders and Small Pharma security holders would own approximately 74.5% and 25.5% of Cybin, respectively.

The combined company will be led by Cybin’s CEO Doug Drysdale. Small Pharma’s senior management …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.